DexCom’s (DXCM) “Buy” Rating Reiterated at BTIG Research

DexCom (NASDAQ:DXCM)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a report released on Friday,Benzinga reports. They currently have a $85.00 price objective on the medical device company’s stock. BTIG Research’s price objective points to a potential upside of 30.61% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. UBS Group decreased their target price on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd. Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a research note on Monday, January 12th. Wells Fargo & Company set a $93.00 target price on shares of DexCom and gave the company an “overweight” rating in a research note on Friday, October 31st. Evercore began coverage on DexCom in a research report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price for the company. Finally, Argus lowered their price target on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.05.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $65.08 on Friday. The company has a market capitalization of $25.38 billion, a PE ratio of 36.16, a price-to-earnings-growth ratio of 1.22 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock has a fifty day moving average of $68.94 and a 200-day moving average of $69.88. DexCom has a one year low of $54.11 and a one year high of $93.25.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the previous year, the firm earned $0.45 earnings per share. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, equities analysts anticipate that DexCom will post 2.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of DexCom during the 4th quarter worth about $483,356,000. Groupama Asset Managment increased its holdings in DexCom by 79,043.1% in the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after buying an additional 4,011,438 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares in the last quarter. Marshall Wace LLP lifted its stake in DexCom by 260.7% in the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after acquiring an additional 2,762,504 shares during the last quarter. Finally, Holocene Advisors LP bought a new stake in DexCom in the third quarter worth approximately $163,964,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat consensus: DXCM reported $0.68 EPS vs. $0.65 expected and revenue of $1.26B (up ~13% YoY), showing continued top-line growth and margin improvement that likely drove buyer interest. Dexcom beats quarterly estimates on strong demand for glucose monitors
• Positive Sentiment: Company press release and investor materials provide supporting detail and guidance context — investors had concrete slides and call access to validate the beat. Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results
• Positive Sentiment: Management commentary/transcripts emphasize robust demand and product momentum (useful for gauging sustainability of growth). DexCom (DXCM) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts remain generally bullish — coverage pieces on target prices keep upside expectations in the market narrative, but targets vary and will influence trading as updates arrive. What Are Wall Street Analysts’ Target Price for DexCom Stock?
• Neutral Sentiment: New product/engagement initiative: a Stelo AI upgrade aims to deepen consumer metabolic-health engagement — potentially expands TAM and recurring revenue if adoption follows. DexCom Stelo AI Upgrade Aims To Deepen Consumer Metabolic Health Engagement
• Neutral Sentiment: Press and transcript coverage (Seeking Alpha, Zacks, Benzinga, SFGATE) provide overlapping recaps — useful for detail but largely reiterate the beat rather than new catalysts. DexCom: Q4 Earnings Snapshot
• Negative Sentiment: Technical/valuation headwinds: DXCM trades below its 50- and 200-day moving averages and carries a relatively high PE (~36x), which could limit near-term upside despite the beat. (Background market data: market cap ~$25.4B, P/E-G ~1.22.)
• Negative Sentiment: Short-interest reporting appears inconsistent (entries showing 0 shares), suggesting noisy/uncertain data on positioning — could add volatility if corrected or if short activity actually rises.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.